-

Sphere Fluidics Strengthens Commercial Team With Three New Senior Hires

  • Evelyn Stevenson joins as Director of Product Management, Ravi Girdhar as Director of Sales in the EMEA region, and Denise Emsden as Vice-President of People and Organizational Development
  • Key appointments form part of broader ongoing recruitment plans to support expanded operations and product development

CAMBRIDGE, England--(BUSINESS WIRE)--Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has appointed three new hires to its commercial team. Evelyn Stevenson and Ravi Girdhar join as Director of Product Management and Director of Sales (EMEA), respectively, alongside Denise Emsden as Vice-President of People and Organizational Development. Following the closure of a £26 million GBP (c. $36 million USD) funding round in 20211, the appointments support the Company’s next stage of development to expand product research and development, international operations and sales in key global markets.

Evelyn Stevenson, BSc, is a global commercial leader with over 20 years’ experience within the life sciences market from companies such as Azenta Life Sciences, Lonza and Thermo Fisher Scientific. Evelyn has extensive experience in business development and managing strategic relationships (both internal and external) to ensure product portfolio strategies are highly aligned to current and future business needs. Evelyn commented, “We have a fantastic opportunity to expand our technology into new markets, have a very exciting product pipeline and a great team behind us”.

Ravi Girdhar, MChem, joins Sphere Fluidics as Director of Sales, EMEA. Over the past decade, Ravi has held various commercial positions within GE Healthcare, Thermo Fisher Scientific and most recently at Gyros Protein Technologies. Ravi stated, “It is an exciting time to join the Sphere Fluidics family as it has become a key emerging player in the single cell analysis research using its patented picodroplet technology. I am thrilled to be a part of the Company’s commercial expansion plans as it continues its ongoing success with an innovative product portfolio and pipeline to help accelerate biopharmaceutical discovery”.

Denise Emsden, FCIPD NEBOSH, joins Sphere Fluidics as VP of People and Organizational Development. Denise is an accomplished Human Resources professional with significant commercial acumen. Experience of working within diverse industries, including life sciences (Abcam, Mundipharma), FMCG (Sainsburys) and Elite Sports (Juddmonte), ensures a balanced, pragmatic and considered approach is taken. Denise noted, “I am very excited to join Sphere Fluidics at this point in their evolution. The opportunity to support the organisation to attract, develop, engage, and retain the best talent to achieve our strategic goals is incredibly compelling for me”.

Dr Frank F Craig, CEO, Sphere Fluidics, saidThis expansion is funded by our recent $40 million fund raise which will help drive the business to greater success. We have also hired some excellent technical and operations staff and are currently also hiring several other senior managers to help develop the commercial and financial teams. These hires, plus a plan for a new facility, demonstrates this pivotal time for the business”.

  1. Press release: Sphere Fluidics closes a $40 million funding round led by Sofinnova Partners and Redmile Group (28th October 2021)

For more information about Sphere Fluidics, please visit: https://spherefluidics.com/

Contacts

Zyme Communications
Ellie Chandrasma
ellie.chandrasma@zymecommunications.com

Sphere Fluidics


Release Versions

Contacts

Zyme Communications
Ellie Chandrasma
ellie.chandrasma@zymecommunications.com

More News From Sphere Fluidics

Sphere Fluidics Rebrands to Sphere Bio

CAMBRIDGE, England--(BUSINESS WIRE)--Sphere Fluidics today announced its rebranding to Sphere Bio. The name change marks a significant milestone in the Company’s development, reflecting its transition from a leading droplet-based microfluidics innovator to an established commercial provider of integrated life sciences tools and solutions. Founded in 2010, the Company has been focused on the development of novel single-cell analysis products and R&D services for a growing portfolio of market...

Sphere Fluidics Launches Cyto-Mine Chroma and Announces Early Access Program

CAMBRIDGE, England--(BUSINESS WIRE)--Sphere Fluidics, a leading provider of innovative picodroplet-based microfluidics solutions for functional single cell analysis and isolation, today announced the launch of Cyto-Mine® Chroma and the opening of its Early Access Program at SLAS2025 International Conference and Exhibition in San Diego. Cyto-Mine Chroma represents the next generation of Sphere Fluidics’ industry-leading Cyto-Mine single-cell analysis platform. The Early Access Program provides a...

Sphere Fluidics Strengthens Global Commercial Teams and Establishes Direct Sales and Support Channel in North America

CAMBRIDGE, England--(BUSINESS WIRE)--Sphere Fluidics, a leading provider of innovative droplet-based microfluidics solutions for functional profiling of single cells at scale, today announced a significant expansion of its global commercial presence. The Company has established a new direct sales and support channel for customers in North America and made several commercial leadership changes globally. These milestones reflect the ongoing strategic focus on operational scale-up to address deman...
Back to Newsroom